Bayer has set end-of-life dates for four MEDRAD® injector platforms across CT, MR, and angiography. The injectors keep working — SEVA Devices keeps the disposables coming, FDA 510(k)-cleared and OEM-grade, so the capital upgrade stays your decision on your timeline.
Bayer’s published EOL notices move the affected platforms through four stages — coverage, service, replacement, and end of support. Mapping those announced dates against your fleet lets you plan ahead instead of reacting under deadline.
The last window to buy full-service coverage for the affected platforms. Already closed for all four.
Service availability narrows and replacement parts become harder to source as the platform nears end of support. The current window for Stellant Classic and Spectris Solaris EP facilities.
Bayer’s recommended successors — Stellant FLEX (CT), MRXperion (MR), and Mark 7 Arterion (Angio) — use new proprietary disposables and require fresh capital, often $20,000–$50,000 per injector head.
Bayer service, parts, consumables, and support end. Without an independent disposables supplier, the equipment goes unsupported.
A platform stays usable only as long as its disposables do. When Bayer’s run out, SEVA’s don’t. SEVA supplies 510(k)-cleared, OEM-grade disposables for all four platforms — so a working injector stays clinically usable through every stage, and the upgrade turns back into your choice, on your timeline.
Every affected MEDRAD platform, its Bayer end-of-service date and recommended upgrade, and the matched SEVA kit that keeps it supplied. One SEVA MR kit (HS-MMD115T) serves both the Spectris Solaris and the Solaris EP.
| Platform | Modality | Bayer EOL | Bayer’s upgrade | SEVA kit | SEVA supply |
|---|---|---|---|---|---|
| MEDRAD Mark V ProVis | Angio | 12/31/2025 | Mark 7 Arterion | HS-MA150 | Continuing |
| MEDRAD Spectris Solaris MR | MR | 12/31/2025 | MRXperion | HS-MMD115T | Continuing |
| MEDRAD Stellant Classic CT | CT | 12/31/2028 | Stellant FLEX + Certegra | HS-DCD201 / HS-DC201 | Continuing |
| MEDRAD Spectris Solaris EP MR / EP Mobile | MR | 12/31/2028 | MRXperion | HS-MMD115T | Continuing |
SEVA kit references per the SEVA Devices product catalog (September 2025). “Bayer’s upgrade” lists the OEM’s recommended replacement, shown for orientation only. The EOL date ends Bayer’s supply — not yours.
The evaluation kit, the cross-reference, the savings model, and the full EOL reference — each one a click away.
A committee-ready dossier — product equivalence, 510(k) status, fleet compatibility, and cost impact — plus matched samples for the injectors you run. Requested through the form so every kit is tied to your dedicated account team.
Request the VAC kit →Every SEVA SKU mapped to its OEM cross-reference across CT, MR, and angiography — each row a stocked, 510(k)-cleared kit.
View the cross-reference →Size your disposable savings against current per-kit pricing for any OEM, with replacement-platform capital shown separately.
Open the calculator →A stage-by-stage timeline, platform by platform, citing Bayer’s own published notices — written for administrators, VACs, and supply chain.
Download the reference →MR-specific transition guidance for the Solaris and Solaris EP — both resupplied by a single SEVA kit, HS-MMD115T.
Download the brief →Angiographic transition guidance for the Mark V, Mark V Plus, and Mark V ProVis — continuing supply with SEVA kit HS-MA150 after the 2025 cutoff.
Download the brief →CT transition guidance for the Stellant Classic ahead of the 2028 cutoff — one supply line across Classic and FLEX with HS-DCD201 and HS-DC201.
Download the brief →Tell us the MEDRAD platforms you run and SEVA returns the matched, 510(k)-cleared kits, the documentation your committee needs, and pricing built around your volume — on your timeline, not Bayer’s.
Request the evaluation kit